

BLINCYTO® (blinatumomab)

Alert Card for Patients and Caregivers

Patient Alert Card

Please show this card to all emergency and healthcare providers

Information about BLINCYTO®▼(blinatumomab)

My name is _____

I am being treated with BLINCYTO, a treatment for acute lymphoblastic leukaemia, which can lower my immune system.

I started treatment on _____

Before providing any treatment, please call my prescribing physician at the number below. If any medical evaluations are undertaken, please provide copies of all medical records, including any treatments and/or test results, to the doctor(s) named below.

	Name	Hospital	City	Phone Number
Haematologist Oncologist				
Haematology Nurse				

BLINCYTO® (blinatumomab)

Alert Card for Patients and Caregivers

This document has been reviewed and approved by The Saudi Food and Drug Authority (SFDA). Contact details for adverse event reporting or to request further information. Any suspected adverse reactions should be reported immediately to local Amgen safety contacts or the National Pharmacovigilance and Drug Safety Center

Amgen Local Safety Contacts

Tel: +966 112 799328

E-mail: Safety-MEA@amgen.com

The National Pharmacovigilance Centre (NPC)

Saudi Food and Drug Authority (SFDA)

SFDA call center 19999

Toll free phone: 8002490000

Fax: +966-11-2057662

E-mail: npc.drug@sfd.gov.sa Online: <http://ade.sfd.gov.sa/>

Should you have any questions or require additional information regarding the use of Blincyto, please contact Medical Information on +966 112 799366 or by e-mail at: meamedinfo@amgen.com